- Home
- CXW vs AGIO Comparison
CXW vs AGIO Comparison
Compare CXW & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXW
- AGIO
- Stock Information
- Founded
- CXW 1983
- AGIO 2007
- Country
- CXW United States
- AGIO United States
- Employees
- CXW N/A
- AGIO N/A
- Industry
- CXW Real Estate Investment Trusts
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- CXW Real Estate
- AGIO Health Care
- Exchange
- CXW Nasdaq
- AGIO Nasdaq
- Market Cap
- CXW 2.4B
- AGIO 2.4B
- IPO Year
- CXW 1997
- AGIO 2013
- Fundamental
- Price
- CXW $18.65
- AGIO $42.08
- Analyst Decision
- CXW Strong Buy
- AGIO Strong Buy
- Analyst Count
- CXW 3
- AGIO 5
- Target Price
- CXW $33.33
- AGIO $57.25
- AVG Volume (30 Days)
- CXW 989.7K
- AGIO 563.1K
- Earning Date
- CXW 11-05-2025
- AGIO 10-30-2025
- Dividend Yield
- CXW N/A
- AGIO N/A
- EPS Growth
- CXW 57.89
- AGIO N/A
- EPS
- CXW 0.95
- AGIO 11.13
- Revenue
- CXW $1,997,643,000.00
- AGIO $40,875,000.00
- Revenue This Year
- CXW $9.19
- AGIO $23.76
- Revenue Next Year
- CXW $10.74
- AGIO $148.23
- P/E Ratio
- CXW $19.76
- AGIO $3.80
- Revenue Growth
- CXW 1.62
- AGIO 30.57
- 52 Week Low
- CXW $12.45
- AGIO $23.42
- 52 Week High
- CXW $24.99
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- CXW 34.17
- AGIO 65.06
- Support Level
- CXW $18.72
- AGIO $39.32
- Resistance Level
- CXW $22.46
- AGIO $41.29
- Average True Range (ATR)
- CXW 0.66
- AGIO 1.27
- MACD
- CXW -0.26
- AGIO 0.33
- Stochastic Oscillator
- CXW 3.21
- AGIO 95.79
About CXW CoreCivic Inc.
CoreCivic Inc is an owner and operator of private prisons and detention centers in the United States. It operates in three segments: Safety, Community, and Properties. The Community segment owns and operates residential reentry centers. The Properties segment owns properties for lease to third parties and government agencies. The vast majority of the company's revenue comes from the CoreCivic Safety segment which consists of correctional and detention facilities that are owned, or controlled via a long-term lease, and managed by the company, as well as those correctional and detention facilities owned by third parties but managed by CoreCivic.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.